Medicus Pharma Ltd. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Medicus Pharma performed this year. My goal is to cut through the corporate jargon so you can decide if this company fits your portfolio.

1. What does this company do?

Medicus Pharma (NASDAQ: MDCX) is a clinical-stage biotech company. They don’t sell products yet, so they have no sales revenue. Instead, they act as a drug development engine. They buy intellectual property, run clinical trials, and aim to sell or license their drugs to large pharmaceutical companies. They focus on oncology and dermatology, specifically targeting areas where current treatments are invasive or ineffective.

2. Major business moves

This year, the company focused on moving their treatments through clinical trials:

• SkinJect: This is their lead project. It is a microneedle patch that delivers chemotherapy directly into skin cancer lesions. They finished enrolling 90 patients for their Phase 2 study and expanded testing into the United Arab Emirates to speed up data collection.
• Antev: In August 2024, they acquired this subsidiary to develop Teverelix, a drug for prostate cancer.

Medicus estimates these two markets represent an $8 billion opportunity.

3. Progress on the "Big Bet" (SkinJect)

The most important news this year is the positive interim data from the SkinJect Phase 2 study. Over 60% of patients saw their lesions completely clear up. The treatment also proved safe, with no serious side effects reported. Furthermore, the FDA gave them a clearer path to Phase 3 trials. This could shorten their development timeline by 12 to 18 months and lower the total cost to reach a final drug application.

4. Financial performance and health

To be blunt: Medicus is not yet profitable. For the 2024 fiscal year, they reported a $14.2 million loss. This came from spending $9.8 million on research and $4.4 million on general business costs.

Because they have no sales, they rely entirely on investors to fund their work. They ended the year with about $3.5 million in cash. To keep running, they have sold more shares to the public. This has caused significant dilution, meaning the company issued more shares and reduced your ownership percentage. The number of shares outstanding grew by 22% this year, which lowers the potential value of your existing shares.

5. Key risks for investors

• The "All-or-Nothing" Nature of Biotech: The company’s value depends entirely on clinical trial results. While SkinJect’s early data is good, Phase 3 trials are larger, costlier, and harder to pass. If these trials fail, the drug could lose all its value.
• The "Going Concern" Warning: Auditors noted that Medicus does not have enough cash to fund operations for the next 12 months. They must raise more money soon. If the market turns or data looks bad, raising that money will be difficult.
• Future Obligations: The Antev acquisition includes a deal to pay up to $65 million if the drug hits certain milestones. While this saves cash today, it is a massive bill they must pay later, likely requiring more share sales or a major partnership.

The Bottom Line: Medicus Pharma is a high-risk, high-reward play. They have promising early data for SkinJect, but their current financial situation is tight. Before investing, ask yourself if you are comfortable with the likelihood of further share dilution and the binary nature of biotech trials, where the company's future hinges on the success of its upcoming clinical milestones.